Business
FDA Expands U.S. Age Indication for EVO ICL as Long-Term Safety Data Reinforces Market Shift Away From Laser Vision Correction
LAKE FOREST, Calif., February 17, 2026--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded age indication for EVO/EVO+ Visian® Implantable Collamer Lenses, extending use to patients 21 to 60 years old. The approval came shortly after publication of three-year FDA clinical trial safety data, reinforcing
About this update from Staar Surgical Company
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/5690899b64b1040b49faf0b000dcdb20"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/DVIt2B25jAmbtCdQzzZz_Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/5690899b64b1040b49faf0b000dcdb20","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/0Wyb9k_4Nk5S_q11Cd6lqw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/5690899b64b1040b49faf0b000dcdb20","width":1024,"height":512}},"lazy":false},{"type":"text","content":"New FDA expansion of U.S. age indication extends EVO ICL use for patients 21 to 60 years old – making EVO ICL available to nearly 8 million additional refractive patients","length":170,"tagName":"p","attribs":{}},{"type":"text","content":"Lens-based vision correction with EVO ICL is now the leading procedure for U.S. patients with -8.0 diopters and above","length":117,"tagName":"p","attribs":{}},{"type":"text","content":"U.S. refractive market continues to shift away from laser-based refractive procedures that require corneal tissue removal","length":121,"tagName":"p","attribs":{}},{"type":"text","content":"LAKE FOREST, Calif., February 17, 2026--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded age indication for EVO/EVO+ Visian® Implantable Collamer Lenses, extending use to patients 21 to 60 years old. The approval came shortly after publication of three-year FDA clinical trial safety data, reinforcing the long-term safety profile of the EVO ICL.1 The EVO ICL was previously approved for U.S. patients 21 to 45 years old. The age range indication expansion helps to further increase the addressable market for the EVO ICL in the U.S. and allow its benefits to be brought to more patients. The achievement of the age range expansion in the U.S. is part of a continuing STAAR effort to expand our EVO ICL offering to a broader patient population globally.","length":969,"tagName":"p"},{"type":"tex...